Review of Chemoradiotherapy for High-Risk Prostate Cancer
Historically, radiation therapy of prostate cancer was associated with significant genitourinary and gastrointestinal morbidity. With advances in radiation therapy techniques and delivery, the potential for safe dose-escalation has emerged. Further, there is an opportunity for chemotherapeutic agents to play an important syngergistic role in radiosensitizing the tumor cells at the primary site while also addressing micrometastatic disease. Concurrent chemoradiation therapy has become standard treatment for many types of locally advanced tumors, including lung, cervical, esophageal, rectal, and anal malignancies. We present a review of clinical trials examining the role of chemoradiation therapy in high-risk prostate cancer.
Keywords: Cancer; DOCETAXEL; Estramustine phosphate; IMRT; Image-Guided Radiation Therapy (IGRT); PACLITAXEL; T4 prostatic adenocarcinoma; Three-Dimensional Conformal Radiotherapy (3DCRT); Vinblastine; chemotherapy; concurrent; cytotoxic anti-microtubule agent; depolymerization; high-risk; plasma testosterone levels; prostate; radiotherapy; tubulin; vinca alkaloid
Document Type: Research Article
Publication date: January 1, 2011
- Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites